

REMARKS

The Examiner is thanked for having graciously held a telephone interview with the undersigned on March 31, 2005.

The March 31, 2005 Advisory Action and the pending claims are discussed. It was agreed that the terminology “acetone/formic acid” (claim 85) is changed to “acetone.” It was also agreed that Applicants would consider resolving the double patenting issue with regard to copending application 10/152,106 by deleting reference to sesquihydrate from the claims of the present application. Applicants note, however, that the double patenting issue can be resolved by filing a terminal disclaimer either in the present application or in the copending application 10/152,106 upon the issuance of one of them as a patent. Applicants respectfully request for another telephone interview with the Examiner to discuss the double patenting issue in the present application in view of the status of the copending application 10/152,106.

Claims 84-93 and 123 are pending in the present application. Applicants have canceled claim 84 without prejudice and amended claims 85 and 86. Support for the amendments to claims 85 and 86 can be found, *inter alia*, in the original claim 84. Therefore, the present Amendment is fully supported by the original specification and does not raise any issue of new matter. In addition, the present Amendment would place the present application in condition for allowance upon a positive resolution of the double patenting issue with regard to copending application 10/152,106. Accordingly, entry of the present Amendment is respectfully requested. Upon entry of the present Amendment, claims 85-93 and 123 will be under examination.

**CONCLUSION**

In view of the claim amendments and the remarks, further and favorable considerations of the presently pending claims are respectfully requested.

It is believed that no fee, other than the \$120.00 one-month extension of time fee, is required for the consideration of this Amendment. However, if any other fees are required, the Commissioner is authorized to charge any such fees to our Deposit Account No. 16-1445.

DATE: April 1, 2005



Lance Y. Liu  
Attorney for Applicants  
Reg. No. 45,379

**Customer No. 28523**  
Pfizer Inc.  
Patent Dept.  
MS 4159  
Eastern Point Road  
Groton, CT. 06340  
(860)686-1652